



The Rise of Direct-to-Consumer Labs and Rx

Why Consumer-Direct Diagnostics and Pharmacy Are Redefining Access to Care

A Unytalk Health White Paper

Mahendra Penumathsa
Founder, CEO

September 2026

Unytalk Inc
203 N La Salle St, Fl 21,
Chicago, IL 60601



www.unytalk.health

Preface

The first Unytalk Health white paper of 2026 presented a picture of primary care independence—separating longitudinal, relationship-based care from insurance-billed, vertically integrated delivery—is not a fringe experiment but a structural response to a strained reimbursement system. Since publishing it, I have watched that thesis extend into two adjacent domains faster than I expected: how consumers order and receive lab tests, and how they obtain prescriptions.

Where independent primary care addresses who delivers the first touchpoint of care, direct-to-consumer labs and pharmacy address how consumers obtain the two most transactional artifacts of medical care—a diagnostic result and a prescription—without first routing through a health plan, a pharmacy benefit manager, or a hospital referral network. The same forces behind the primary care shift—claim denial fatigue, administrative friction, price opacity, and a consumer base increasingly comfortable transacting healthcare like any other digital purchase—are now visible in diagnostics and pharmacy at even greater velocity and scale.

In 2025 and 2026, the change became hard to ignore. Legacy laboratories built consumer storefronts, drug manufacturers began selling directly to cash-paying patients, the federal government launched its own direct-to-consumer drug portal, and regulators started drawing sharper lines around what telehealth companies can claim. At the same time, employers facing record pharmacy cost increases began looking for direct, transparent alternatives.

This white paper is my attempt to map that shift: the market momentum, the regulatory scaffolding, the value for each stakeholder, and the practical pathways for physicians and platforms. My goal, as before, is to highlight the signals worth tracking, grounded in a practical need: keeping testing and treatment accessible and affordable for the communities that rely on them.

Disclaimer(s):

All products and company names are trademarks of their respective owners. Any references are for identification only and do not imply endorsement or partnership.

All data and figures attributed to third-party studies are illustrative and are not intended to endorse them. This white paper does not vouch for the accuracy of the references made in the attributed sources. This white paper is for informational and educational purposes only and does not constitute legal, tax, investment, or medical advice; readers should consult qualified professionals before acting upon the insights presented herein.

This document is suitable for generating awareness of, and helping readers interpret, broad and emerging trends in direct-to-consumer diagnostics and pharmacy models, but it is not intended as an offer or solicitation of securities and should not be treated as advertising or promotional material under any specific regulatory regime.

The author has drawn on publicly available datasets and reputable third-party research, supported by AI-assisted literature review and summarization tools; all quoted data are attributed to their original published sources. Market, pricing, and regulatory information reflects sources available as of September 2026 and are subject to change.

Table of Contents

1. Introduction and Audience	6
Who is this for?	6
Scope and purpose.....	6
2. The Diagnostics and Pharmacy Access Crisis	7
Price opacity and lab price variation	7
Prescription affordability and cost-related nonadherence	7
Prior authorization and PBM friction	8
Pharmacy closures and access deserts	8
3. Consumer-Directed Labs and Rx: Concept & Rationale	9
What is consumer-directed diagnostics and pharmacy?.....	9
How labs and Rx differ from the primary care visit	9
The clinical and economic case.....	9
Regulatory and market enablers.....	10
4. Direct-to-Consumer Labs and Rx Models Explained.....	11
What is direct-access testing?	11
What is D2C pharmacy and telehealth prescribing?	11
D2C vs. insurance-routed pathways	12
Hybrid models and variations	12
Legal and Practical Boundaries	13
Statewise regulatory considerations.....	13
5. Market Momentum and 2026-2030 Inflections	14
Market size and growth trajectory	14
Platform and incumbent growth.....	14
Manufacturer direct and TrumpRx.....	15
Employer adoption as accelerant	15
State and Federal Policy Momentum.....	16
Technology and AI Integration	16
2026 Inflection Point.....	17
6. Value Proposition for Stakeholders.....	17
7. Implementation Pathways and Readiness Considerations.....	19
8. Conclusions and Call to Action.....	22
9. References.....	25

Executive Summary

American consumers are paying more, waiting longer, and navigating more intermediaries to obtain two of the most routine artifacts of medical care: a lab result and a prescription.

Employer-sponsored insurance pays hospital outpatient departments about 3.4 times more than independent laboratories for identical tests [1]. Forty-three percent of adults report not taking a medication as prescribed because of cost [2], and roughly 2,000 pharmacy locations closed in 2025 alone [3].

Direct-to-Consumer (D2C) laboratory testing and D2C prescription (Rx) models offer a transparent, fast-scaling alternative. By publishing cash prices, removing prior authorization from routine purchases, and delivering tests and medications directly to the consumer, these models extend the logic of independent primary care into diagnostics and pharmacy. The global D2C lab testing market is estimated at USD 3.99 billion in 2026 and projected to reach USD 6.48 billion by 2031 [4], while the U.S. online pharmacy market is forecast to grow from USD 43.24 billion in 2025 to USD 189.74 billion by 2034 [5]. Quest Diagnostics' consumer-initiated testing grew more than 20% in 2025 [6], Hims & Hers reached USD 2.35 billion in 2025 revenue [7], and TrumpRx.gov now lists more than 1,000 medicines [8].

This white paper examines why consumer-directed diagnostics and pharmacy are becoming an essential layer of accessible care for 2026 and beyond. We explore the systemic failures driving the shift, the regulatory boundaries that shape it, the market momentum accelerating adoption, and the value proposition for physicians, patients, employers, and communities. While the third and final paper in this series will address how payers and carriers are likely to respond, this document establishes the operational and market case for D2C labs and Rx.

The evidence is clear: once patients establish a direct relationship with their primary care physician, the lab order and the prescription must become equally direct, transparent, and affordable.

1. Introduction and Audience

Who is this for?

This white paper addresses independent and direct primary care physicians evaluating diagnostic and pharmacy partnerships, digital health platform builders and investors assessing the direct-to-consumer (D2C) labs and prescription (Rx) opportunity, employer benefits leaders and consultants evaluating direct-contracting alternatives to legacy pharmacy benefit arrangements, and health plan and policy leaders tracking where consumer self-direction ends and clinical oversight begins.

Scope and purpose

This white paper is the second in Unytalk Health’s 2026 series. The first paper established why primary care is separating from insurance-driven, vertically integrated delivery [9]. This paper follows the same logic into the two most transactional layers of care that sit immediately downstream of a primary care visit: the lab order and the prescription.

We examine:

- The price opacity, affordability, and access failures in insurance-routed diagnostics and pharmacy
- The rationale for consumer-directed testing and pharmacy as an extension of independent primary care
- How D2C lab and Rx models work, and the federal and state rules that bound them
- Current market dynamics and the 2026–2030 inflection points
- Value propositions for physicians, patients, employers, and communities
- Practical implementation pathways and readiness considerations

This white paper provides the “what and how” of consumer-directed diagnostics and pharmacy, building on the “why” of primary care independence.

2. The Diagnostics and Pharmacy Access Crisis

Price opacity and lab price variation

Clinical laboratory testing is one of the most standardized services in medicine, yet it is priced as if it were bespoke. Roughly 14 billion clinical lab tests are ordered each year in the United States, performed by about 260,000 laboratories [1]. For identical tests, employer-sponsored insurance paid hospital outpatient departments about 3.4 times more than physician offices and independent laboratories in 2019; the median comprehensive metabolic panel cost \$47.13 in a hospital outpatient setting versus \$8.85 in an office or independent lab [1].

Site-of-care markups: Hospital outpatient labs accounted for 54% of lab spending in the same sample, and their spending grew 32% from 2012 to 2019 versus 1% for offices and independent labs [1].

The uninsured penalty: A 2024 comparison of 42 Florida hospitals found a mean uninsured price of \$401 for a complete blood count, compared with \$88 at insurance-negotiated rates and \$32 through direct-to-consumer channels from Quest Diagnostics and Labcorp—roughly a 12-fold gap [10].

Insured patients are not protected: In the same study, one Medicare Advantage patient paid \$245 out of pocket for a physician-ordered HbA1c test that cost \$39 through a CLIA-certified D2C laboratory [10].

Prescription affordability and cost-related nonadherence

Two-thirds of U.S. adults (66%) currently take at least one prescription drug and 31% take four or more; 59% say they are worried about affording their prescription costs [2]. In KFF's February–March 2026 polling, 43% of adults reported not taking a medication as prescribed because of cost—substituting an over-the-counter product, not filling a prescription, or cutting pills and skipping doses [2].

Federal survey data point in the same direction. Among adults aged 18–64 taking prescription drugs, 9.2 million (8.2%) did not take their medication as prescribed to reduce costs in 2021, rising to 22.9% among the uninsured and 20.0% among adults with disabilities [11]. Out-of-pocket retail drug spending reached \$63 billion that year [11].

The GLP-1 era has made the problem visible to the mainstream. About 12% of adults currently use a GLP-1 medication, and a majority—including 55% of those with health insurance—say the drugs are difficult to afford [2].

Prior authorization and PBM friction

Prior authorization delays: In an AMA survey of 1,000 practicing physicians published in May 2026, 95% said prior authorization delays access to necessary care, 79% reported that patients abandon treatment because of authorization hurdles, and 26% reported that prior authorization had caused a serious adverse event [12]. Only 33% believed the June 2025 insurer pledge to streamline prior authorization would make a meaningful difference [12].

Middleman markups: The Federal Trade Commission found that the three largest pharmacy benefit managers (PBMs) marked up numerous specialty generic drugs by hundreds or thousands of percent at their affiliated pharmacies, generating more than \$7.3 billion in dispensing revenue above estimated acquisition cost between 2017 and 2022, plus an estimated \$1.4 billion from spread pricing [13].

Concentration: The six largest PBMs manage about 94% of U.S. prescriptions, and the three largest process nearly 80% of roughly 6.6 billion prescriptions a year [14]. The consumer rarely sees any of these economics at the counter.

Pharmacy closures and access deserts

The retail pharmacy footprint is contracting. Roughly 2,000 fewer pharmacy locations existed at the end of 2025: about 1,250 Rite Aid stores closed after its Chapter 11 filing, Walgreens closed around 500, and CVS closed 270 [3]. An estimated one in seven people live in a pharmacy desert, defined as a drive of at least 15 minutes to the nearest pharmacy [3]. Although Walgreens now expects to close far fewer stores in 2026 than originally planned [15], the structural signal is clear: brick-and-mortar pharmacy access can no longer be assumed.

Mail and home delivery increasingly fill the gap. Brookings estimates that about 2.9 million Medicare beneficiaries live in areas that combine limited pharmacy access with high mail-order use, and notes that mail-order programs are associated with 30–40% higher medication adherence than retail pharmacy use [16]. The consumer-direct channel is becoming infrastructure, not just convenience.

3. Consumer-Directed Labs and Rx: Concept & Rationale

What is consumer-directed diagnostics and pharmacy?

Consumer-directed diagnostics and pharmacy means allowing a patient to initiate, purchase, and receive a lab test or a medication through a transparent, direct channel—rather than routing every step through a health plan, a PBM formulary, or a hospital referral network. It does not remove clinicians from the loop; it changes who initiates the transaction and how it is priced.

Where independent primary care addresses who delivers the first touchpoint of care, D2C labs and Rx address how consumers obtain the two most transactional artifacts of medical care—a diagnostic result and a prescription—with the same directness, price transparency, and speed that membership-based primary care offers [9].

How labs and Rx differ from the primary care visit

The primary care visit is relational and longitudinal. Labs and prescriptions are transactional and repeatable, which makes them well suited to direct pricing:

Standardization: A lipid panel or a 30-day supply of a generic medication is functionally identical across sites of care, so price differences reflect channel economics rather than clinical value [1].

Frequency: Chronic disease management depends on repeat testing and refills. Each unnecessary insurance touchpoint compounds friction over months and years.

Price sensitivity: Consumers on high-deductible plans often pay the full negotiated price for tests and drugs, which can exceed the cash price available through a direct channel [10].

Separability: Labs and pharmacy can be unbundled from the visit and fulfilled by specialized, CLIA-certified laboratories and licensed pharmacies, while the clinical relationship remains with the physician.

The clinical and economic case

Lower unit prices: D2C lab prices are generally lower than insurance-negotiated, physician-ordered hospital lab prices, and dramatically lower than uninsured hospital prices [10].

Better adherence through delivery: In a Kaiser Permanente Northern California study of 17,217 patients with diabetes, mail-order pharmacy users under age 65 had fewer all-cause emergency department visits (34.0% vs. 40.2%) than local-pharmacy-only users [17].

Faster time to treatment: Direct pathways remove prior authorization and network steps that physicians report delay care and lead to treatment abandonment [12].

Engagement and prevention: Consumer-initiated testing can prompt earlier conversations about cardiometabolic, hormonal, and nutritional risk; yet 63% of Americans do not know they can purchase their own lab tests without a doctor's visit [18], suggesting substantial latent demand.

The case is not unconditional. A 2025 review in Clinical Chemistry cautions that aggressive marketing and poorly interpreted results can cause psychological, physical, and financial harm [19]. The strongest models pair consumer access with physician interpretation—which is precisely where independent primary care fits.

Regulatory and market enablers

Laboratory policy stability: A federal court vacated the FDA's 2024 rule treating laboratory-developed tests (LDTs) as medical devices in March 2025, and the FDA formally rescinded the rule in September 2025, returning LDTs to enforcement discretion [20][21].

Manufacturer direct pricing: Executive Order 14297 (May 2025) directed HHS to facilitate direct-to-consumer purchasing at most-favored-nation prices [22], and TrumpRx.gov launched on February 5, 2026 [23].

Tax-advantaged funding: The One Big Beautiful Bill Act permanently restored the HDHP telehealth safe harbor and, starting January 1, 2026, allows HSA-eligible individuals to pay qualifying direct primary care fees (up to \$150 per month individual, \$300 family) from their HSAs [24].

PBM reform: The Consolidated Appropriations Act, 2026 requires PBMs to pass through 100% of manufacturer rebates to employer plans and to provide detailed reporting, with requirements generally effective for calendar-year plans on January 1, 2029 [25].

These developments create a more favorable environment for consumer-directed diagnostics and pharmacy than at any time in the past two decades.

4. Direct-to-Consumer Labs and Rx Models Explained

What is direct-access testing?

Direct access testing (DAT) is consumer-initiated testing of human specimens, also called direct-to-consumer or patient-authorized testing [26]. In a typical D2C lab model, the consumer:

- Selects a test or panel online and pays a published cash price
- Has the order reviewed and authorized by an independent physician network where state law requires it
- Provides a specimen at a patient service center or through an at-home collection kit
- Receives results digitally, often with clinician follow-up for out-of-range values

Quest Diagnostics' consumer site illustrates the model: an independent third-party physician reviews every test request, may review results, and for some conditions can provide a prescription for treatment [18].

What is D2C pharmacy and telehealth prescribing?

The D2C prescription landscape has evolved along three parallel tracks:

Telehealth-plus-Rx platforms: Companies such as Hims & Hers, Ro, and LifeMD combine an online clinical evaluation with home delivery of the prescribed medication, increasingly bundled with lab testing [27].

Transparent cash-pay pharmacies: Mark Cuban Cost Plus Drug Company prices medications at acquisition cost plus 15%, a \$5 pharmacy fee, and \$5 shipping, and now offers more than 2,500 medications [14]. Amazon Pharmacy's RxPass gives Prime members in 48 states access to more than 50 common medications for \$5 per month [28].

Manufacturer-direct channels: LillyDirect, NovoCare Pharmacy, and the federal TrumpRx.gov portal offer self-pay prices directly to consumers. The Wegovy pill launched in January 2026 at \$149 per month for the starting dose [29], and Lilly's Foundayo (orforglipron) pill launched in April 2026 at \$149 for self-pay [30].

D2C vs. insurance-routed pathways

Direct-to-consumer labs and Rx differ from the traditional insurance-routed pathway in five key aspects:

Aspect	Insurance-Routed Pathway	Direct-to-Consumer Pathway
Initiation	Physician order, often after a visit and referral	Consumer-initiated, with physician review where required
Pricing	Negotiated rates hidden until the bill; deductible exposure	Published cash price before purchase
Authorization	Prior authorization, step therapy, formulary rules	None for cash purchase; clinical appropriateness still required
Fulfillment	Hospital or network lab; retail or PBM-affiliated pharmacy	Independent CLIA lab or at-home kit; home delivery pharmacy
Data flow	Results to ordering physician; claims to payer	Results to consumer and chosen physician; no claim required

D2C does not replace insurance for complex diagnostics or high-cost specialty drugs; it creates a transparent lane for the routine, repeatable portion of testing and treatment [31].

Hybrid models and variations

Pure cash-pay D2C: The consumer pays the published price with no claim submitted. Common for wellness panels, generics, and self-pay GLP-1 programs [6].

Membership-bundled testing: Subscription platforms such as Function Health bundle 100+ biomarkers into an annual membership using Quest patient service centers [32][33].

Physician-integrated D2C: Independent and direct primary care practices order labs at negotiated cash rates and route prescriptions to transparent pharmacies, keeping interpretation within the longitudinal relationship [9].

Employer-sponsored direct: Employers contract directly with manufacturers or transparent pharmacies—for example, Lilly’s Employer Connect offers Zepbound to employers at a net \$449 per month with no rebates [34].

Insurer-integrated transparent pharmacy: Health plans such as Capital Blue Cross and independent PBMs such as LucyRx now route members to cost-plus pharmacies for selected drugs and biosimilars [35][36].

Legal and Practical Boundaries

D2C lab and Rx purchases are not a substitute for comprehensive health insurance. They typically do not cover:

- Complex, high-risk, or genetic diagnostics requiring specialist interpretation
- Specialty and infused medications requiring clinical administration
- Controlled substances beyond what federal telemedicine rules and state law allow
- Hospitalization, emergency, or specialty care triggered by abnormal results

Cash purchases may also not count toward insurance deductibles unless submitted and accepted by the plan, and TrumpRx prices are cash-only and do not process insurance claims [37].

Consumers need to understand this trade-off.

Statewise regulatory considerations

Statewise regulations vary significantly for D2C labs and Rx:

Direct access testing: CLIA regulates laboratories, not who orders tests; state laboratory laws determine whether consumers may order their own tests, and some states do not allow DAT [26][38]. New York, for example, permits DAT only for specific tests by laboratories holding a state permit [39]. National operators must build state-specific physician-authorization workflows [40].

Telehealth prescribing: States require a bona fide practitioner-patient relationship, and many specify that an online questionnaire alone does not meet the standard of care [41][42].

Controlled substances: DEA and HHS extended COVID-era telemedicine flexibilities for prescribing controlled medications without a prior in-person visit through December 31, 2026, while permanent rules are finalized [43].

Pharmacy licensure and certification: Pharmacies shipping across state lines must be licensed in each destination state, and platforms that advertise prescription drugs or pharmacy services commonly need LegitScript certification to use major advertising and payment platforms [44].

Successful D2C lab and Rx offerings require careful legal structuring tailored to state-specific requirements.

5. Market Momentum and 2026-2030 Inflections

Market size and growth trajectory

Estimates for the D2C laboratory testing market vary by methodology and scope, but every major forecaster projects sustained high single to double-digit growth:

Source	Base Market Size	Forecast	CAGR
Mordor Intelligence (global)	USD 3.99B (2026)	USD 6.48B by 2031	10.19%
Precedence Research (global)	USD 4.08B (2026)	USD 8.69B by 2035	8.77%
Precedence Research (U.S.)	USD 1.34B (2026)	USD 2.92B by 2035	9.03%
Towards Healthcare (global)	USD 4.12B (2026)	USD 8.90B by 2035	8.94%
Technavio (global)		+USD 28.57B growth, 2025–2030	36.8%

Sources: Mordor Intelligence [4]; Precedence Research [45]; Towards Healthcare [46]; Technavio [47].

The prescription side is scaling faster. The U.S. online pharmacy market was valued at USD 43.24 billion in 2025 and is projected to reach USD 189.74 billion by 2034 (17.86% CAGR), with prescription medicines accounting for 74.2% of the market [5]. The U.S. direct-to-consumer telehealth services market was projected to grow from USD 1.47 billion in 2023 to USD 9.53 billion by 2030 (30.3% CAGR) [48], within a broader U.S. telehealth market forecast to grow from roughly USD 78 billion in 2025 to nearly USD 679 billion by 2035 [49].

Platform and incumbent growth

Both legacy laboratories and digital-first entrants are reporting rapid consumer growth:

Platform	Model	Recent Signal
Quest Diagnostics	Consumer-initiated testing (questhealth.com)	Consumer-initiated testing grew >20% in 2025; questhealth.com grew ~35% to a \$100M run rate [6]
Labcorp	Labcorp OnDemand	Double-digit consumer growth; 200+ biomarkers and a new genetic health panel in 2026 [50]
Function Health	Membership lab testing	\$298M Series B at a \$2.5B valuation; 50M+ lab tests since 2023 [32]
Hims & Hers	Telehealth + Rx + Labs	2025 revenue of \$2.35B (+59%); nearly 2.9M subscribers in Q2 2026 [7][51]

Platform	Model	Recent Signal
GoodRx	Discounts + manufacturer direct	Pharma Direct revenue up 41% in 2025 to \$151.4M [52]
Amazon Pharmacy	Full-service online pharmacy	Same-day delivery expanding to ~4,500 U.S. cities and towns by end of 2026 [28]
Cost Plus Drugs	Cost-plus transparent pharmacy	2,500+ medications; partnerships with Humana CenterWell, insurers, and PBMs [14][53]

Consumer demand is also reshaping clinical practice. In a Doximity survey reported by STAT, about two-thirds of roughly 200 physicians said patients had brought D2C test results to visits, yet fewer than 10% said their institution had clear guidance on handling them [33].

Manufacturer direct and TrumpRx

Manufacturer participation has accelerated sharply. In 2025, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk, and others announced direct-to-consumer sales and price cuts in response to federal pricing pressure [54]. TrumpRx.gov launched with roughly 40 drugs in February 2026, expanded to 87 by late April [31], and, according to the White House, now covers more than 1,000 branded and generic medicines with more than \$700 million in reported savings [8].

Independent analysis suggests a more nuanced picture. A KFF comparison of 32 brand-name drugs found TrumpRx prices lower than peer-country averages for 17 drugs and higher for 15 [37], and GoodRx reported that early TrumpRx demand has been concentrated in weight-loss drugs and largely incremental [55]. The channel is real; the savings are uneven.

Employer adoption as accelerant

Self-insured employers are becoming the fastest-moving buyers of direct pharmacy arrangements:

- Employer drug spending rose about 9% in 2026, the fourth consecutive annual increase, and total benefit costs were expected to rise 6.7%, the highest increase in 15 years [56]
- Nearly 30% of large employers tightened GLP-1 utilization controls, and 6% dropped GLP-1 coverage in 2026 [56]

- Lilly's Employer Connect lets employers buy Zepbound at a net \$449 per month through 18 administrators, including GoodRx, Cost Plus Drugs, Transcarent, and a direct primary care group [34]
- Employers are expected to shift toward transparent, pass-through PBMs and carve out GLP-1 coverage through direct programs [57]

Humana's CenterWell Pharmacy and Cost Plus Drugs are jointly building end-to-end employer prescription solutions, starting with Humana's own workforce [53].

State and Federal Policy Momentum

PBM reform: The Consolidated Appropriations Act, 2026 delinks PBM compensation from drug prices in Medicare Part D and imposes rebate pass-through, reporting, and audit requirements on PBMs serving employer plans [58][25].

Medicare pricing: Negotiated prices for the first 10 Medicare Part D drugs took effect on January 1, 2026 [59]. The Medicare GLP-1 Bridge, launched July 1, 2026, gives eligible beneficiaries certain GLP-1 drugs for \$50 per month [60], and has been extended through 2027 alongside the CMS BALANCE Model [61].

Advertising enforcement: In September 2025 the FDA sent thousands of letters warning against misleading direct-to-consumer drug advertising [62], followed by 30 warning letters to telehealth companies in March 2026 and 25 more in June 2026 over compounded GLP-1 claims [63][64].

Technology and AI Integration

The 2026 technology landscape reinforces D2C labs and Rx viability. Platforms increasingly combine:

- Online ordering and published pricing for lab panels, with results delivered to the consumer's phone
- At-home specimen collection and same-day or next-day medication delivery
- AI-assisted interpretation of biomarker trends, with physician review for abnormal results
- Integrated subscription models linking testing, prescribing, refills, and follow-up

Hims & Hers, for example, has positioned AI and technology investment as the path to making high-touch, comprehensive care more affordable [51]. The convergence of testing, prescribing,

and delivery into a single consumer journey creates a powerful platform for accessible, transparent care.

2026 Inflection Point

Multiple trends converge in 2026–2028 to create an inflection point for D2C labs and Rx adoption:

1. **Price transparency goes mainstream:** Manufacturer-direct portals, TrumpRx, and cost-plus pharmacies have made cash prices visible to consumers for the first time at national scale [31][14].
2. **Regulatory clarity on labs:** The LDT rule’s vacatur and rescission removed a major overhang for laboratory innovation [21].
3. **Enforcement sets the rules of the road:** FDA action against misleading compounded-drug marketing is separating durable, compliant platforms from opportunistic ones [63][64].
4. **Employer cost pressure:** Double-digit drug-spend pressure and GLP-1 costs are pushing employers toward direct contracting [56][34].
5. **Consumer behavior:** One in eight adults now uses a GLP-1, and many obtain them outside traditional channels—17% of GLP-1 users reported getting them from an online provider [65].

These factors position 2026–2030 as the critical window when D2C labs and Rx transition from alternative to mainstream channels.

6. Value Proposition for Stakeholders

For physicians: clinical control, speed, and simpler operations

D2C labs and Rx extend the autonomy that independent primary care restores:

Faster diagnosis and treatment: Ordering labs at transparent cash rates and routing prescriptions to direct pharmacies removes prior authorization steps that 95% of physicians say delay care [12].

Affordable plans patients can follow: When physicians can quote the real price of a test or medication, they can design treatment plans patients will actually complete, reducing the cost-related nonadherence reported by 43% of adults [2].

Interpretation as the value layer: With two-thirds of physicians already seeing D2C results in the exam room [33], the physician's role shifts toward interpretation, prioritization, and longitudinal follow-up—the core strengths of relationship-based primary care.

Practice economics: For direct primary care practices, negotiated cash lab pricing and transparent pharmacy access are differentiating membership benefits that do not require insurance billing infrastructure [9].

For patients: price, access, and control

Price certainty: Patients see the price before they buy; D2C lab prices are generally below insurance-negotiated hospital prices and far below uninsured prices [10].

Access without detours: No referral, no network restrictions, and no waiting for authorization for routine tests and generic medications.

Delivery to the door: Home delivery supports adherence and fills gaps left by pharmacy closures [16][3].

Ownership of data: Results are delivered directly to the consumer, who can share them with the physician of their choice.

For patients with chronic conditions, frequent monitoring needs, or high-deductible plans, the value proposition is compelling: predictable costs, faster answers, and medication they can afford to take as prescribed.

For employers: cost control and measurable outcomes

Direct pricing without rebate games: Manufacturer-direct programs such as Lilly Employer Connect offer net pricing with no rebates [34], and cost-plus pharmacies publish their markup formula [14].

Transparency ahead of the mandate: Employers do not have to wait for CAA 2026 PBM reforms to take effect in 2029; transparent pass-through PBMs and direct pharmacy arrangements are available now [25][57].

Targeted GLP-1 strategy: Rather than dropping coverage entirely, employers can offer structured, lower-cost direct access with clinical support [56][34].

Integrated primary care, labs, and Rx: Pairing employer-sponsored direct primary care with transparent labs and pharmacy creates a single, measurable front door for routine care [9].

For communities: access and health equity

Pharmacy deserts: Home delivery and mail-order extend medication access to rural and underserved communities where retail pharmacies have closed [28][16].

The uninsured: Cash-price D2C labs can reduce the uninsured cost of routine tests by an order of magnitude [10].

Cost-related nonadherence: Adults who are uninsured, disabled, or in fair or poor health face the highest rates of skipping medications due to cost [11]; transparent generic pricing directly addresses this gap.

D2C labs and Rx alone will not solve healthcare inequity, but they provide a practical lane for affordable testing and treatment in communities that the traditional system has underserved.

7. Implementation Pathways and Readiness Considerations

Standard and transition models

Physicians, practices, and platforms can pursue multiple pathways to D2C labs and Rx:

Referral-partner model: Direct patients to established consumer channels (Quest, Labcorp OnDemand, Cost Plus Drugs, manufacturer-direct programs) and review results in the practice. Lowest effort, but limited control of the experience [6][50].

Negotiated cash-price model: Contract directly with a CLIA-certified reference laboratory for member pricing and publish a lab price list to patients. Common among direct primary care practices [26].

Integrated pharmacy model: Route prescriptions to transparent cash-pay or cost-plus pharmacies, and where state law permits, dispense common generics in-office. Requires attention to state dispensing rules.

Employer-bundled model: Package primary care, labs, and pharmacy into a single per-employee offering, including access to manufacturer-direct employer programs [34].

Platform-integrated model: Use a digital platform that connects the physician, the patient, the laboratory, and the pharmacy in one workflow—ordering, results, prescribing, and refills—so the patient never has to re-enter the insurance-mediated system between visit, test, and treatment.

Readiness checklist

Organizations considering D2C labs and Rx should assess:

Clinical governance:

- Who reviews and authorizes consumer-initiated orders in each state?
- How are critical and abnormal results escalated and followed up?
- Which tests and medications are appropriate for direct access, and which are not?

Regulatory environment:

- Does each target state permit direct access testing, and for which tests?
- Are prescribing workflows compliant with state patient-relationship requirements and DEA rules?
- Are pharmacy partners licensed in every destination state and appropriately certified?

Partner selection:

- Are laboratory partners CLIA-certified and accredited for the tests offered?
- Do pharmacy partners dispense FDA-approved products, with any compounding clearly labeled?
- Are pricing terms transparent and contractually stable?

Consumer experience and marketing:

- Are prices published clearly, including what is and is not included?
- Do marketing claims distinguish FDA-approved drugs from compounded products?
- Is it clear to consumers when cash purchases do not count toward insurance deductibles?

Technology and data:

- Can results flow into the practice's record and back to the patient securely?
- Is the platform HIPAA-compliant with clear consent for data sharing?
- Can the practice track adherence, refills, and follow-up testing?

Common pitfalls and success factors

Pitfalls to avoid:

- **Blurred product claims:** Implying compounded drugs are equivalent to FDA-approved products invites enforcement [63][64]
- **Testing without interpretation:** Selling panels without clinician follow-up creates anxiety, incidental findings, and low-value care [19]
- **Ignoring state variation:** Launching nationally without state-specific DAT and prescribing workflows [40]
- **Opaque pricing:** Hidden fees or unclear inclusions erode the trust that D2C depends on

Success factors:

- **Anchor in a physician relationship:** Pair consumer access with a clinician who knows the patient [9]
- **Lead with transparency:** Publish prices, sources, and what each product is and is not
- **Start with high-value use cases:** Chronic disease monitoring, preventive panels, and high-volume generics
- **Partner with established, compliant suppliers:** CLIA-certified labs and licensed, certified pharmacies [44]
- **Measure outcomes:** Track adherence, time to treatment, and total cost for patients and employers

Resources and support networks

Multiple organizations provide guidance for D2C labs and Rx:

- **Centers for Medicare & Medicaid Services (CLIA program):** Laboratory certification and direct access testing guidance [26]
- **American Society for Clinical Pathology:** Policy and quality guidance on direct access testing [38]

- **American Academy of Family Physicians:** State telehealth and prescribing requirements [42]
- **LegitScript:** Certification for pharmacies and telehealth providers [44]
- **FDA:** Guidance on compounded GLP-1s and prescription drug promotion [66][62]

8. Conclusions and Call to Action

The case for transformation

The evidence presented throughout this white paper supports a clear conclusion: routine diagnostics and prescriptions no longer need to be routed through insurance-centric, opaque channels. Identical lab tests vary in price by multiples across sites of care [1][10], 43% of adults report not taking medications as prescribed because of cost [2], and PBM markups on specialty generics have been documented in the billions [13].

Direct-to-consumer labs and Rx offer a transparent, scalable alternative. Consumer testing is growing at double-digit rates for incumbents and startups alike [6][32], telehealth-plus-Rx platforms are reaching millions of subscribers [51], and manufacturers and the federal government have made direct cash pricing a mainstream distribution strategy [54][31].

The 2026–2030 window represents a unique inflection point. Price transparency, regulatory clarity on labs, stricter enforcement on marketing claims, and employer cost pressure converge to create optimal conditions. Organizations that act now can build trusted, compliant consumer channels before the market consolidates.

Remaining barriers and the payer question

While the case for D2C labs and Rx is compelling, significant barriers remain:

Fragmented data: Consumer-initiated results often never reach the patient’s physician, and fewer than 10% of physicians report clear institutional guidance for handling them [33].

Uneven savings: Direct prices are not always the lowest available, and some TrumpRx prices exceed peer-country averages [37].

Regulatory complexity: State DAT rules, telehealth prescribing standards, and the scheduled end of DEA telemedicine flexibilities in December 2026 require continuous compliance attention [26][43].

Insurance interaction: Cash purchases generally do not count toward deductibles, forcing consumers to choose between price transparency and benefit accumulation.

These challenges point to a broader structural question that the third and final Unytalk Health white paper of 2026 will address: as consumers take ownership of primary care, diagnostics, and pharmacy, how will carriers and payers restructure incentives, benefit design, and risk models—encouraging consumer-initiated primary and preventive care while concentrating underwriting on secondary and tertiary care, where cost and clinical complexity remain concentrated?

Call to action

For independent and direct primary care physicians: Build transparent lab and pharmacy pathways into your membership model now. Negotiate cash lab pricing, identify compliant pharmacy partners, and position your practice as the interpretation and follow-up layer for consumer-initiated testing.

For digital health platforms: Treat regulatory literacy as a moat. Sell FDA-approved or clearly labeled, legitimately compounded products; partner with CLIA-certified labs; and connect the consumer journey back to a physician relationship.

For employers and benefits consultants: Do not wait for 2029. Evaluate transparent pass-through PBMs, manufacturer-direct employer programs, and cost-plus pharmacies, and pilot integrated primary care, labs, and Rx offerings with measurable outcomes.

For health plans and policymakers: Recognize that consumer-directed channels can reduce the cost of routine care. Design benefits that credit transparent cash purchases and integrate D2C data into care coordination.

For early-stage investors and family offices: The D2C labs and Rx market offers durable growth, clear regulatory tailwinds for compliant operators, and strong alignment with affordability goals.

The shift of diagnostics and pharmacy from insurance-routed, opaque channels to transparent, consumer-directed access is not hypothetical—it is underway. The question is not whether this shift will occur, but which physicians, platforms, employers, and investors will lead it.

9. References

- [1] Health Care Cost Institute & West Health. (2022). Price Markups for Clinical Labs: Employer-based Insurance Pays Hospital Outpatient Departments 3X More Than Physician Offices and Independent Labs for Identical Tests. https://healthcostinstitute.org/wp-content/uploads/images/pdfs/HCCI_labprices_brief_051223.pdf
- [2] KFF. (2026, March 31). Public Opinion on Prescription Drugs and Their Prices. <https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/>
- [3] Modern Retail. (2026, January 2). Pharmacy closures in 2025 reshaped where people buy health products. <https://www.modernretail.co/operations/pharmacy-closures-in-2025-reshaped-where-people-buy-health-products/>
- [4] Mordor Intelligence. (2026). Direct-to-Consumer Laboratory Testing Market Size & Share Analysis, 2026–2031. <https://www.mordorintelligence.com/industry-reports/direct-to-consumer-laboratory-testing-market>
- [5] Market Data Forecast. (2026). United States Online Pharmacy Market Size & Share Report, 2026–2034. <https://www.marketdataforecast.com/market-reports/united-states-online-pharmacy-market>
- [6] Quest Diagnostics. (2026, February 10). Q4 2025 Earnings Call. <https://www.alphaspread.com/security/nyse/dgx/investor-relations/earnings-call/q4-2025>
- [7] Hims & Hers Health, Inc. (2026, February 23). Fourth Quarter and Full Year 2025 Financial Results. <https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx>
- [8] The White House. (2026, September 18). President Trump Extends Most Favored Nation Pricing to Every Medicaid Program in America. <https://www.whitehouse.gov/releases/2026/09/president-trump-extends-most-favored-nation-pricing-to-every-medicaid-program-in-america/>
- [9] Penumathsa, M. (2026, February). Independent Primary Care Transformation: Why Direct-To-Consumer Models Are a Trend to Watch Now. A Unytalk Health White Paper. Unytalk Inc. <https://www.unytalk.health>
- [10] Cost Comparisons of Physician-Ordered Versus Direct-to-Consumer Laboratory Testing. (2024). Cureus, 16(11), e74173. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11663041/>
- [11] National Center for Health Statistics, CDC. (2023). Characteristics of Adults Aged 18–64 Who Did Not Take Medication as Prescribed to Reduce Costs: United States, 2021 (NCHS Data Brief No. 470). <https://www.cdc.gov/nchs/products/databriefs/db470.htm>
- [12] American Medical Association. (2026, May 13). AMA survey: Prior authorization reform pledge falls short for physicians. <https://www.ama-assn.org/press-center/ama-press-releases/ama-survey-prior-authorization-reform-pledge-falls-short-physicians>
- [13] Federal Trade Commission. (2025, January 14). FTC Releases Second Interim Staff Report on Prescription Drug Middlemen. <https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-releases-second-interim-staff-report-prescription-drug-middlemen>
- [14] DrugPatentWatch. (2026). Mark Cuban's Cost Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling. <https://www.drugpatentwatch.com/blog/mark-cubans-cost-plus-drugs-vs-big-pharma-the-strategic-war-you-need-to-be-modeling-right-now/>
- [15] Cleveland.com. (2026, September 25). Walgreens is closing far fewer stores than anyone expected in 2026. <https://www.cleveland.com/business/2026/09/walgreens-is-closing-far-fewer-stores-than-anyone-expected-heres-the-surprising-new-number-in-2026.html>
- [16] Brookings Institution. (2025, December 4; amended September 17, 2026). When slower mail becomes a health risk. <https://www.brookings.edu/articles/when-slower-mail-becomes-a-health-risk/>

- [17] Schmittiel, J. A., et al. (2013). The safety and effectiveness of mail order pharmacy use in diabetes patients. American Journal of Managed Care, 19(11), 882–887. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4278640/>
- [18] Quest Diagnostics / The Harris Poll. (2025, May 20). More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score. <https://newsroom.questdiagnostics.com/2025-05-20-More-Americans-Know-Their-Streaming-Platform-Passwords-by-Heart-Than-Their-Cholesterol-Score,-New-Survey-Reveals>
- [19] Orth, M., Sandberg, S., & Shih, P. (2025). Direct-to-Consumer Testing: Benefits and Concerns of Commercially Accessed Laboratory Tests. Clinical Chemistry, 71(6), 652–663. <https://academic.oup.com/clinchem/article/71/6/652/8020500>
- [20] American Clinical Laboratory Association. (2025, March 31). Federal Court Vacates FDA Rule on Laboratory Developed Testing Services. <https://www.acla.com/federal-court-vacates-fda-rule-on-laboratory-developed-testing-services-siding-with-acla/>
- [21] American Hospital Association. (2025, September 18). FDA vacates final rule regulating lab-developed tests as medical devices. <https://www.aha.org/news/headline/2025-09-18-fda-vacates-final-rule-regulating-lab-developed-tests-medical-devices>
- [22] The White House. (2025, May 12). Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. <https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/>
- [23] The White House. (2026, February 5). Fact Sheet: President Donald J. Trump Launches TrumpRx.gov. <https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trump-rx-gov-to-bring-lower-drug-prices-to-american-patients/>
- [24] Bradley Arant Boult Cummings. (2025, July 23). Employee Benefits Under the One Big Beautiful Bill Act: What Employers Need to Know. <https://www.bradley.com/insights/publications/2025/07/employee-benefits-under-the-one-big-beautiful-bill-act-what-employers-need-to-know>
- [25] Mercer. (2026, February 5). Extensive PBM transparency reforms now law. <https://www.mercer.com/en-us/insights/us-health-news/extensive-pbm-transparency-reforms-now-law/>
- [26] Centers for Medicare & Medicaid Services. (2019). Direct Access Testing (DAT) and the Clinical Laboratory Improvement Amendments (CLIA) Regulations. <https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/directaccesstestingpdf.pdf>
- [27] Hims & Hers Health, Inc. (2025, November 13). Hims & Hers Introduces Labs. <https://investors.hims.com/news/news-details/2025/Hims--Hers-Introduces-Labs-a-Holistic-In-Depth-Testing-Experience-That-Puts-Customers-in-Control-of-Their-Health-and-Wellness-Journeys/default.aspx>
- [28] Amazon. (2026, February 11). Amazon Pharmacy will expand Same-Day medication delivery to nearly 4,500 U.S. cities and towns by year-end. <https://press.aboutamazon.com/2026/2/amazon-pharmacy-will-expand-same-day-medication-delivery-to-nearly-4-500-u-s-cities-and-towns-by-year-end>
- [29] Novo Nordisk. (2026, January 5). Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America. <https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html>
- [30] Eli Lilly and Company. (2026, April 1). FDA approves Lilly's Foundayo (orforglipron). <https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill>
- [31] Congressional Research Service. (2026, July 31). TrumpRx: Background and Implementation (IF13281). https://www.congress.gov/crs_external_products/IF/PDF/IF13281/IF13281.1.pdf

- [32] TechCrunch. (2025, November 19). Function Health raises \$298M Series B at a \$2.5B valuation. <https://techcrunch.com/2025/11/19/function-health-closes-298m-series-b-at-a-2-5b-valuation-launches-medical-intelligence/>
- [33] STAT. (2026, January 9). As more patients order lab tests online, doctors don't know what to do with the results. <https://www.statnews.com/2026/01/09/patients-ordering-lab-tests-screenings-online-frustrate-doctors/>
- [34] CNBC. (2026, March 5). Eli Lilly launches program to boost employer coverage of obesity drugs. <https://www.cnbc.com/2026/03/05/eli-lilly-launches-program-to-boost-employer-coverage-of-obesity-drugs.html>
- [35] Central Penn Business Journal. (2026, May 11). Capital Blue Cross enhances collaboration with Mark Cuban Cost Plus Drug Co. <https://www.cpbj.com/capital-blue-cross-enhances-collaboration-with-mark-cuban-cost-plus-drug-co-by-covering-humira-and-stelara-biosimilars/>
- [36] LucyRx. (2026, August 11). LucyRx Expands Pharmacy Access with Mark Cuban Cost Plus Drug Company. <https://lucyrx.com/press-releases/lucyrx-expands-pharmacy-access-cost-plus-drugs/>
- [37] USA TODAY. (2026, September 25). TrumpRx claims the world's lowest drug prices. A new report raises doubts. <https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/25/how-trump-rx-drug-prices-compare-to-peer-nations/91925351007/>
- [38] American Society for Clinical Pathology. Policy Statement: Direct Access Testing. <https://www.ascp.org/content/docs/default-source/policy-statements/ascp-pdf-tpp-direct-access-testing.pdf>
- [39] New York State Department of Health, Wadsworth Center. Direct Access Testing. <https://www.wadsworth.org/regulatory/clep/direct-access-testing>
- [40] Wheel. (2021). Direct-to-consumer lab testing: legal, regulatory, and clinical considerations for companies. <https://www.wheel.com/blog/direct-to-consumer-lab-testing-legal-regulatory-and-clinical-considerations-for-companies>
- [41] American Medical Association. (2018). 50-State Survey: Establishment of a Patient-Physician Relationship via Telemedicine. <https://www.ama-assn.org/system/files/2018-10/ama-chart-telemedicine-patient-physician-relationship.pdf>
- [42] American Academy of Family Physicians. Legal Requirements for Telehealth. <https://www.aafp.org/practice-operations/telehealth-and-telemedicine/legal-requirements-for-telehealth>
- [43] U.S. Department of Health and Human Services. (2026, January 2). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. <https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html>
- [44] LegitScript. (2026). Healthcare Certification. <https://www.legitscript.com/certification/healthcare-certification/>
- [45] Precedence Research. (2026). Direct-To-Consumer Laboratory Testing Market Size, 2026–2035. <https://www.precedenceresearch.com/direct-to-consumer-laboratory-testing-market>
- [46] Towards Healthcare. (2026). Direct-To-Consumer Laboratory Testing Market Sizing, 2026–2035. <https://www.towardshealthcare.com/insights/direct-to-consumer-laboratory-testing-market-sizing>
- [47] Technavio. Direct-to-Consumer Laboratory Testing Market Analysis, 2025–2030. <https://www.technavio.com/report/direct-to-consumer-laboratory-testing-market-analysis>
- [48] Research and Markets. (2024). U.S. Direct to Consumer Telehealth Services Market Size, 2023–2030. <https://www.researchandmarkets.com/report/united-states-direct-to-consumer-telehealth-services-market>
- [49] Nova One Advisor. U.S. Telehealth Market Size, 2025–2035. <https://www.novaoneadvisor.com/report/us-telehealth-market>

- [50] Labcorp. (2026, July 30). Labcorp Announces 2026 Second Quarter Results. <https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2026-second-quarter-results-raises-full-year>
- [51] Hims & Hers Health, Inc. (2026, August 10). Second Quarter 2026 Financial Results. <https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Second-Quarter-2026-Financial-Results/default.aspx>
- [52] GoodRx Holdings, Inc. (2026, February 25). GoodRx Reports Fourth Quarter and Full Year 2025 Results. <https://investors.goodrx.com/news-releases/news-release-details/goodrx-reports-fourth-quarter-and-full-year-2025-results/>
- [53] Word & Brown JR Report. (2026, May 5). Humana, Mark Cuban's Cost Plus Drugs Plan to Offer New Employer Prescription Solutions. <https://jrreport.wordandbrown.com/2026/05/05/humana-mark-cubans-cost-plus-drugs-plan-to-offer-new-employer-prescription-solutions/>
- [54] Reuters. (2025). Pharma companies announce direct-to-consumer sales, price cuts in the US. <https://www.reuters.com/business/healthcare-pharmaceuticals/big-pharma-firms-announce-direct-to-consumer-sales-price-cuts-us-2025-10-13/>
- [55] POLITICO. (2026, August 7). Prescription Pulse: A window into TrumpRx's demand. <https://www.politico.com/newsletters/prescription-pulse/2026/08/07/a-window-into-trumprxs-demand-01028208>
- [56] Healthcare Dive. (2026, June 18). Employers plan to shift more health costs to employees: Mercer. <https://www.healthcaredive.com/news/employers-shift-more-health-costs-on-employees-mercer/822891/>
- [57] SmithRx. (2026, January 1). Pharmacy Benefits Shakeup: 2026 Trends and Predictions. <https://smithrx.com/blog/2026-pharmacy-benefits-trends-and-predictions>
- [58] KFF. (2026, February 9). What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation. <https://www.kff.org/other-health/what-to-know-about-pharmacy-benefit-managers-pbms-and-federal-efforts-at-regulation/>
- [59] KFF. (2026, March 11). Key Facts About Medicare Drug Price Negotiation. <https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/>
- [60] Centers for Medicare & Medicaid Services. (2026, July 1). CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications. <https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications>
- [61] KFF. (2026, May 11). What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. <https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/>
- [62] U.S. Food and Drug Administration. (2025, September 9). FDA Launches Crackdown on Deceptive Drug Advertising. <https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising>
- [63] U.S. Food and Drug Administration. (2026, March 3). FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. <https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s>
- [64] McDermott Will & Emery. (2026, June 30). FDA takes aim at misleading online claims for compounded GLP-1 drugs. <https://www.mcdermottlaw.com/insights/fda-takes-aim-at-misleading-online-claims-for-compounded-glp-1-drugs/>
- [65] KFF. (2025, November 14). KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. <https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/>

[66] U.S. Food and Drug Administration. (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. <https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>